Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation vs Continuation of 3TC in HIV with Resistance
NCT00143728Phase 4Suspended
- Sponsor
- University of British Columbia
- Start
- Jan 2004
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of British Columbia. Primary endpoint: Virologic failure (VL > 50 copies/mL) at 24 weeks. Started Jan 2004; status: suspended.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00143728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143728.